2017
Nov
27
LimmaTech Biologics will be attending the Annual Meeting of the Antibody Society in San Diego from 11 through 15 December 2017.
OCT
25
LimmaTech Biologics will be attending the PEGS Europe in Lisbon from 13 through 17 November 2017.
OCT
11
Award Winning Paper
LimmaTech Biologics is very pleased to announce that the paper on the “Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial” received an award from The Swiss Society for Infectious Diseases in the category “clinical research in infectious diseases”.
We like to thank all the people involved in this achievement.
SEP
29
LimmaTech Biologics will be attending the Immunogenicity & Bioassay Summit in Washington, USA from 23 through 26 October 2017.
SEP
29
LimmaTech Biologics will be attending the Bio Europe in Berlin, Germany from 7 through 9 November 2017.
SEP
25
LimmaTech Biologics will be attending the 2nd Human Challenge Trials Conference in Rockville, USA from 28 through 30 September 2017.
JUN
16
LimmaTech Biologics will be attending the Vaccines for Enteric Diseases in Albufeira, Portugal from 9 through 11 October 2017.
JUN
16
LimmaTech Biologics will be attending the World Vaccine Congress Europe in Barcelona from 10 through 12 October 2017.
Dr Amir Faridmoayer to present.
MAY
03
LimmaTech Biologics will be attending the 19th EUROCARB in Barcelona from 2 through 6 July 2017.
APR
27
LimmaTech Biologics will be attending the 13th Annual Protein Engineering Summit in Boston from 1 through 5 May 2017.
APR
10
LimmaTech Biologics will be attending the 27th European Congress of Clinical Microbiology and Infectious Diseases in Vienna from 22 through 25 April 2017.
FEB
01
LimmaTech Biologics will be attending the World Vaccine Congress in Washington from 10 through 12 April 2017.
Dr. Michael Kowarik to present.
JAN
19
LimmaTech Biologics will be attending the Biobetters and Next-Generation Biologics: Innovative Strategies for Optimally Effective Therapies (A7) in Snowbird, USA from 22 through 26 January 2017.